Raf Inhibitor Compounds
AssigneesDeciphera Pharmaceuticals, LLC, Eli Lilly and Company
InventorsMatthew Carl Allgeier, Daniel L. Flynn, Michael D. Kaufman, Phenil J. Patel, Craig D. Wolfangel
Life of this patent
Estimating the term…
Abstract
The present invention provides a pyrido[2,3-d]pyrimidine compound, or a pharmaceutically acceptable salt thereof, that inhibits Raf and, therefore, may be useful in treating cancer.
Claims23
-16. (canceled)
A compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
A pharmaceutical composition comprising a compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof, and polyvinyl pyrrolidone vinyl acetate (PVP-VA).
A method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl) phenyl) urea, or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of thyroid cancer, ovarian cancer, melanoma, acute myelogenous leukemia (AML), and colorectal cancer.
Dependencies are inferred from the claim text.